Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

Pharmacy, Oncology, Medical Oncology +8

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

A. Hilary Calvert, David R. Newell, Lindsey Gumbrell et al. · Journal of Clinical Oncology · 1989 · 1.9K citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

Demetrios Papahadjopoulos, Theresa M. Allen, Alberto Gabizón et al. · Proceedings of the National Academy of Sciences · 1991 · 1.6K citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

Maurie Markman, Robert Rothman, Thomas B. Hakes et al. · Journal of Clinical Oncology · 1991 · 854 citations

Medicine, Gynecology, Oncology +13

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 751 citations · Full text

Medicine, Oncology, Pharmacology +17